Pemvidutide

Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcoholic steatohepatitis (NASH). Pemvidutide incorporates the EuPort^TM domain, a proprietary technology that increases its serum half-life for weekly dosing and may slow the entry of pemvidutide into the bloodstream for improved tolerability. Pemvidutide also has been shown to substantially decrease the amount of fat within the liver which could have beneficial effects on insulin resistance and cardiorenal risk, common problems in people with obesity. In clinical trials, pemvidutide demonstrated striking reductions in body weight, liver fat, serum lipids and markers of liver inflammation.

Pemvidutide is a dual receptor agonist that can activate both GLP-1 and glucagon receptors and thereby mimic the complementary effects of diet and exercise on weight loss. The GLP-1 activity of pemvidutide is expected to suppress appetite while its glucagon activity is expected to increase energy expenditure and the burning of fat. By combining GLP-1 and glucagon activity in a single peptide containing a EuPort domain, pemvidutide has the potential to achieve significant weight loss without the need for a long and inconvenient dose-titration regimen.

It is estimated that nearly 80 million¹ people in the United States have non-alcoholic fatty liver disease (NAFLD). If unaddressed, NAFLD may progress to NASH, where excess fat in the liver causes chronic inflammation leading to fibrosis, and eventually cirrhosis. Currently, there are no approved treatments for NASH.

Currently, Altimmune is working on an initiation of a Phase 2b NASH trial planned for mid-year 2023.

The ability of pemvidutide to rapidly, and significantly, reduce liver fat content, liver inflammation and body weight is unique among current NASH therapeutic candidates.